Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Neoadjuvant cisplatin fails to beat standard AC in HER2-negative breast cancer
Key clinical point: For patients with newly diagnosed HER2-negative breast cancer who are BRCA carriers, neoadjuvant cisplatin does not offer a higher pathologic complete response rate than standard doxorubicin/cyclophosphamide.
Major finding: Platinum-based chemotherapy was associated with an 18% pCR rate, compared with 26% for standard doxorubicin/cyclophosphamide, which translated to a risk ratio of 0.70 that was not significant.
Study details: The phase 2 INFORM trial involved 118 patients with HER2-negative breast cancer.
Disclosures: The investigators disclosed relationships with Merck, AstraZeneca, Genentech, and others.
Citation:
Tung N et al. SABCS 2019, Abstract GS6-03.